Akero Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. (ticker: AKRO) is a United States-based biotechnology company listed on the Nasdaq market in the United States. It is a clinical-stage specialty biotech focused on severe metabolic liver disease, with its investment case anchored on the development of therapies for MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH. For international investors, Akero should be viewed primarily as a science- and execution-driven story rather than a diversified commercial pharma platform: the company’s equity value is largely tied to the success of its lead clinical program and to its ability to translate clinical data into regulatory and ultimately commercial value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1744659/000095017025029514/akro-20241231.htm?utm_source=openai)) Akero was founded in 2018 with backing from Apple Tree Partners, and early financing supported the development of its first lead candidate. The company established its headquarters in San Francisco and later South San Francisco, California, placing it in the core US biotech ecosystem. This matters strategically: Akero is built like a typical West Coast clinical biotech, with a lean operating model, a high R&D intensity, and a capital structure designed to fund multi-year clinical development before any commercial launch. ([ir.akerotx.com](https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-closes-65-million-series-financing-advance/?utm_source=openai)) The company’s core asset is efruxifermin, or EFX, an FGF21 analog. According to SEC filings, EFX is Akero’s lead product candidate and the basis of its clinical platform. The drug is being developed as a potential treatment for patients with MASH, including both pre-cirrhotic and compensated cirrhotic disease. That concentration on a single program creates a classic biotech risk/reward profile: if the clinical data continue to support a meaningful efficacy and safety profile, Akero could emerge as a leading metabolic disease specialist; if results disappoint, the downside can be material because the pipeline is relatively concentrated. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1744659/000095017025029514/akro-20241231.htm?utm_source=openai)) From a competitive standpoint, Akero operates in a crowded and strategically important segment of liver and metabolic medicine, where multiple companies are pursuing market share in MASH. Akero’s differentiation lies in its FGF21-based mechanism and the depth of its clinical development around EFX. The company does not yet have a commercial product, so its valuation depends heavily on trial readouts, safety observations, regulatory momentum, and management credibility with institutional investors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1744659/000095017025029514/akro-20241231.htm?utm_source=openai)) Geographically, Akero remains largely US-centered in operations, with headquarters in California and R&D activity concentrated in the United States, even though the disease burden it targets is global. Recent company communications in 2025 indicate continued advancement of multiple clinical trials for EFX, while SEC Form 4 filings show ongoing insider-transaction activity that investors may monitor for governance and sentiment signals. In short, Akero is a Nasdaq-listed United States biotech story built around a single lead asset, a high-unmet-need indication, and a catalyst-heavy clinical timeline. ([akerotx.com](https://akerotx.com/?utm_source=openai))